Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.59
TEVA's Cash to Debt is ranked lower than
71% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. TEVA: 0.59 )
Ranked among companies with meaningful Cash to Debt only.
TEVA' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.33 Max: N/A
Current: 0.59
Equity to Asset 0.55
TEVA's Equity to Asset is ranked lower than
61% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. TEVA: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
TEVA' s Equity to Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.50 Max: 0.6
Current: 0.55
0.39
0.6
Interest Coverage 7.91
TEVA's Interest Coverage is ranked lower than
68% of the 475 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.69 vs. TEVA: 7.91 )
Ranked among companies with meaningful Interest Coverage only.
TEVA' s Interest Coverage Range Over the Past 10 Years
Min: 3.6  Med: 11.22 Max: 305.33
Current: 7.91
3.6
305.33
F-Score: 6
Z-Score: 2.19
M-Score: -2.43
WACC vs ROIC
4.72%
3.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.10
TEVA's Operating margin (%) is ranked higher than
62% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.73 vs. TEVA: 12.10 )
Ranked among companies with meaningful Operating margin (%) only.
TEVA' s Operating margin (%) Range Over the Past 10 Years
Min: 8.12  Med: 17.14 Max: 25.46
Current: 12.1
8.12
25.46
Net-margin (%) 9.13
TEVA's Net-margin (%) is ranked higher than
62% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.01 vs. TEVA: 9.13 )
Ranked among companies with meaningful Net-margin (%) only.
TEVA' s Net-margin (%) Range Over the Past 10 Years
Min: 5.73  Med: 14.73 Max: 20.75
Current: 9.13
5.73
20.75
ROE (%) 6.60
TEVA's ROE (%) is ranked lower than
52% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.15 vs. TEVA: 6.60 )
Ranked among companies with meaningful ROE (%) only.
TEVA' s ROE (%) Range Over the Past 10 Years
Min: 4.23  Med: 11.88 Max: 18.76
Current: 6.6
4.23
18.76
ROA (%) 3.48
TEVA's ROA (%) is ranked lower than
51% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. TEVA: 3.48 )
Ranked among companies with meaningful ROA (%) only.
TEVA' s ROA (%) Range Over the Past 10 Years
Min: 2.26  Med: 6.13 Max: 10.71
Current: 3.48
2.26
10.71
ROC (Joel Greenblatt) (%) 33.29
TEVA's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.13 vs. TEVA: 33.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TEVA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 16.41  Med: 33.56 Max: 49.79
Current: 33.29
16.41
49.79
Revenue Growth (3Y)(%) 4.80
TEVA's Revenue Growth (3Y)(%) is ranked lower than
53% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. TEVA: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TEVA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.8  Med: 16.60 Max: 23.4
Current: 4.8
4.8
23.4
EBITDA Growth (3Y)(%) 10.70
TEVA's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 553 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. TEVA: 10.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TEVA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.5  Med: 15.50 Max: 47.3
Current: 10.7
-10.5
47.3
EPS Growth (3Y)(%) 4.80
TEVA's EPS Growth (3Y)(%) is ranked lower than
54% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. TEVA: 4.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TEVA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -26  Med: 15.80 Max: 68.2
Current: 4.8
-26
68.2
» TEVA's 10-Y Financials

Financials (Next Earnings Date: 2016-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

TEVA Guru Trades in Q2 2015

George Soros 423,308 sh (New)
John Paulson 2,030,500 sh (New)
Larry Robbins 2,844,400 sh (New)
Steven Cohen 179,500 sh (+97.25%)
Jim Simons 2,075,763 sh (+55.03%)
Manning & Napier Advisors, Inc 336,513 sh (+8.06%)
Pioneer Investments 1,155,466 sh (+0.69%)
Ronald Muhlenkamp 176,915 sh (+0.12%)
Michael Price 440,300 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Stanley Druckenmiller Sold Out
Charles Brandes Sold Out
Andreas Halvorsen Sold Out
Vanguard Health Care Fund Sold Out
John Keeley 36,280 sh (-1.51%)
Barrow, Hanley, Mewhinney & Strauss 9,862,843 sh (-3.21%)
David Dreman 90,345 sh (-9.77%)
First Eagle Investment 3,756,998 sh (-10.66%)
Richard Snow 1,603,308 sh (-11.29%)
NWQ Managers 2,984,606 sh (-18.66%)
Paul Tudor Jones 400,000 sh (-27.27%)
Diamond Hill Capital 138,189 sh (-30.78%)
» More
Q3 2015

TEVA Guru Trades in Q3 2015

Andreas Halvorsen 8,872,650 sh (New)
John Paulson 18,000,000 sh (+786.48%)
Steven Cohen 373,800 sh (+108.25%)
Larry Robbins 4,188,779 sh (+47.26%)
Pioneer Investments 1,639,229 sh (+41.87%)
Jim Simons 2,878,763 sh (+38.68%)
First Eagle Investment 4,467,011 sh (+18.90%)
Ronald Muhlenkamp 176,955 sh (+0.02%)
Michael Price 440,300 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Bernard Horn 65,600 sh (unchged)
George Soros Sold Out
Manning & Napier Advisors, Inc 335,793 sh (-0.21%)
John Keeley 35,990 sh (-0.80%)
Barrow, Hanley, Mewhinney & Strauss 9,522,401 sh (-3.45%)
Richard Snow 1,377,992 sh (-14.05%)
NWQ Managers 2,408,826 sh (-19.29%)
David Dreman 42,892 sh (-52.52%)
Diamond Hill Capital 11,525 sh (-91.66%)
Paul Tudor Jones 10,300 sh (-97.43%)
» More
Q4 2015

TEVA Guru Trades in Q4 2015

John Griffin 4,000,000 sh (New)
Julian Robertson 595,300 sh (New)
Louis Moore Bacon 31,994 sh (New)
Ray Dalio 24,100 sh (New)
Vanguard Health Care Fund 5,800,000 sh (New)
Paul Tudor Jones 400,000 sh (+3783.50%)
Andreas Halvorsen 25,043,775 sh (+182.26%)
Larry Robbins 5,955,796 sh (+42.18%)
John Paulson 20,409,300 sh (+13.39%)
John Keeley 36,385 sh (+1.10%)
Barrow, Hanley, Mewhinney & Strauss 9,602,463 sh (+0.84%)
Bernard Horn 65,600 sh (unchged)
Louis Moore Bacon 100,000 sh (unchged)
Ronald Muhlenkamp 176,955 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Michael Price 440,300 sh (unchged)
Samuel Isaly 399,000 sh (unchged)
Diamond Hill Capital Sold Out
David Dreman Sold Out
First Eagle Investment 4,371,619 sh (-2.14%)
Richard Snow 1,262,350 sh (-8.39%)
NWQ Managers 1,380,143 sh (-42.70%)
Manning & Napier Advisors, Inc 113,223 sh (-66.28%)
Pioneer Investments 354,962 sh (-78.35%)
Jim Simons 532,500 sh (-81.50%)
Steven Cohen 28,300 sh (-92.43%)
» More
Q1 2016

TEVA Guru Trades in Q1 2016

Signature Select Canadian Fund 97,300 sh (New)
David Dreman 33,983 sh (New)
Jim Simons 1,191,263 sh (+123.71%)
NWQ Managers 1,961,208 sh (+42.10%)
Andreas Halvorsen 32,971,622 sh (+31.66%)
John Keeley 43,784 sh (+20.34%)
Vanguard Health Care Fund 6,356,700 sh (+9.60%)
Ray Dalio 24,700 sh (+2.49%)
John Paulson 20,602,200 sh (+0.95%)
Ronald Muhlenkamp 177,160 sh (+0.12%)
NWQ Managers 41,600 sh (unchged)
Michael Price 440,300 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Samuel Isaly 399,000 sh (unchged)
Louis Moore Bacon Sold Out
Pioneer Investments Sold Out
Steven Cohen Sold Out
John Griffin 3,988,300 sh (-0.29%)
Manning & Napier Advisors, Inc 111,192 sh (-1.79%)
Barrow, Hanley, Mewhinney & Strauss 9,315,460 sh (-2.99%)
Larry Robbins 5,579,312 sh (-6.32%)
Richard Snow 1,142,923 sh (-9.46%)
Julian Robertson 356,200 sh (-40.16%)
First Eagle Investment 1,915,660 sh (-56.18%)
Paul Tudor Jones 10,782 sh (-97.30%)
» More
» Details

Insider Trades

Latest Guru Trades with TEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF902.004.057 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:TKPYY, NYSE:ZTS, NAS:MYL, OTCPK:ESALY, OTCPK:SGIOF, OTCPK:MKGAY, NYSE:PRGO, OTCPK:APNHY, OTCPK:MTZPY, NYSE:RDY, OTCPK:TAISF, OTCPK:HLUYY, OTCPK:HKMPY, NYSE:VRX, NYSE:MNK, OTCPK:MDABY, NYSE:TARO, OTCPK:SFOSF, NAS:OPK, OTCPK:HYPMY » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVJF.USA,
Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil.

Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments generic and specialty medicines. The generics segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients ("API"). The specialty segment engages in the development, manufacture, sale and distribution of branded specialty medicines such as those for central nervous system and respiratory indications, as well as those marketed in the women's health, oncology and other specialty businesses. Its other activities include the over-the-counter ("OTC") medicines business, distribution activity mainly in Israel and Hungary and medical devices. The OTC activity is mainly conducted through a joint venture with P&G, which combines Company's production capabilities and market reach with P&G's marketing expertise and expansive platform. It has market presence in the United States, Europe and other markets. The Generic medicines include chemical and therapeutic equivalents of originator medicines in dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty medicines include several franchises in the core therapeutic areas of CNS medicines such as Copaxone, Azilect, Nuvigil and Zecuity and of respiratory medicines such as ProAir HFA and QVAR. It also includes other therapeutic areas, such as oncology medicines, including Treanda, women's health and selected other areas. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").

Guru Investment Theses on Teva Pharmaceutical Industries Ltd

John Keeley Comments on Teva Pharmaceuticals - Apr 26, 2016

Teva Pharmaceuticals (NYSE:TEVA) also had a challenging quarter. Although earnings were in-line with expectations, the company announced that its acquisition of Allergan’s generic pharmaceutical business would be delayed. Subsequent to the failure of the Pfizer/Allergan merger due to the proposed tax inversion regulatory changes, Teva announced that its acquisition of Allergan’s generic business remains on track to close in the second quarter of 2016.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Bernard Horn Comments on Teva Pharmaceutical - Mar 21, 2016

Teva Pharmaceutical (NYSE:TEVA) achieved strong profits, noting better-than-expected Copaxone sales. The company’s strategic initiatives, including the takeover of Allergan’s Actavis generic drug business and the joint venture with Takeda in Japan, were well received. This will further cement Teva’s position as the global leader in generics and help the company negotiate with its customers.

From Bernard Horn (Trades, Portfolio)'s Global Value Fund annual letter 2015.



Check out Bernard Horn latest stock trades

Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd - Mar 27, 2015

We trimmed into strength our position in Teva (TEVA), an Israel-based global biopharmaceutical company specializing in generic formulations. The stock rose substantially on a combination of speculation around M&A in the sector, enthusiasm for the new CEO, and the strong conversion of once-daily Copaxone to the three-times-a-week version.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

Andreas Halvorsen Buys Facebook, Amazon, MasterCard Guru's largest 1st-quarter buys
Andreas Halvorsen (Trades, Portfolio) is a founding partner of Viking Global Investors LP and currently serves as its CIO. During the first quarter he bought shares in the following stocks: Read more...
John Keeley Comments on Teva Pharmaceuticals Guru stock highlight
Teva Pharmaceuticals (NYSE:TEVA) also had a challenging quarter. Although earnings were in-line with expectations, the company announced that its acquisition of Allergan’s generic pharmaceutical business would be delayed. Subsequent to the failure of the Pfizer/Allergan merger due to the proposed tax inversion regulatory changes, Teva announced that its acquisition of Allergan’s generic business remains on track to close in the second quarter of 2016. Read more...
Health Care Investor Larry Robbins Buys HCA Holdings, Cigna Top 4th quarter buys from Glenview Capital founder
Glenview Capital Management, founded in 2000 by Larry Robbins (Trades, Portfolio), is a privately held investment management firm. During the fourth quarter, he bought shares in many stocks, including the following.  Read more...
Bernard Horn Comments on Teva Pharmaceutical Guru stock highlight
Teva Pharmaceutical (NYSE:TEVA) achieved strong profits, noting better-than-expected Copaxone sales. The company’s strategic initiatives, including the takeover of Allergan’s Actavis generic drug business and the joint venture with Takeda in Japan, were well received. This will further cement Teva’s position as the global leader in generics and help the company negotiate with its customers. Read more...
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Event and distressed strategies investor ups Valeant stake by 50%
John Paulson (Trades, Portfolio) is the president and portfolio manager of Paulson & Co. Inc. Paulson was ranked by Absolute Return Magazine as the third-largest hedge fund in the world managing approximately $29 billion in merger, event and distressed strategies. During the fourth quarter, the guru bought the following stocks. Read more...
Andreas Halvorsen Raises Stake in Teva Pharmaceutical Guru reduces holdings in Netflix, Walgreens Boots Alliance, MasterCard, Alphabet
Andreas Halvorsen (Trades, Portfolio), founding partner and CIO of Viking Global Investors LP, added two dozen stakes to his portfolio in the fourth quarter, but his most noteworthy activity was the increase of his stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), an Israeli pharmaceutical company, by more than 182%. Read more...
Julian Robertson Buys 8 New Stakes in 4th Quarter Guru's investments include Teva Pharmaceutical, Dollar Tree
Julian Robertson (Trades, Portfolio) of Tiger Management made eight new buys in a wide range of sectors in the fourth quarter. His preferred sectors, Technology and Healthcare, were well represented. Read more...
CME Group Among Guru Stocks With Growing Yield Investment ideas with high dividend yields
The following are companies with high and growing dividend yields that gurus are buying according to GuruFocus' All-in-One Screener. Read more...
John Griffin Invests in Teva Pharmaceutical Guru adds to holdings in Autodesk and Allergan in 4th quarter
John Griffin (Trades, Portfolio), president of Blue Ridge Capital, made five new buys in the fourth quarter, three of which had impacts on his portfolio exceeding 1.5%. Read more...
Gurus Are Buying High-Yield Stocks Like WestRock, Target Investment ideas with increasing dividend yields
The following are companies with high and growing dividend yields that gurus are buying according to GuruFocus' All-in-One Screener. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 28.47
TEVA's P/E(ttm) is ranked higher than
50% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.41 vs. TEVA: 28.47 )
Ranked among companies with meaningful P/E(ttm) only.
TEVA' s P/E(ttm) Range Over the Past 10 Years
Min: 10.49  Med: 20.41 Max: 938.25
Current: 28.47
10.49
938.25
Forward P/E 10.31
TEVA's Forward P/E is ranked higher than
79% of the 81 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. TEVA: 10.31 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.47
TEVA's PE(NRI) is ranked higher than
50% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.39 vs. TEVA: 28.47 )
Ranked among companies with meaningful PE(NRI) only.
TEVA' s PE(NRI) Range Over the Past 10 Years
Min: 10.49  Med: 20.41 Max: 938.25
Current: 28.47
10.49
938.25
Price/Owner Earnings (ttm) 29.29
TEVA's Price/Owner Earnings (ttm) is ranked higher than
59% of the 282 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.57 vs. TEVA: 29.29 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TEVA' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.09  Med: 17.85 Max: 67.1
Current: 29.29
9.09
67.1
P/B 1.87
TEVA's P/B is ranked higher than
67% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. TEVA: 1.87 )
Ranked among companies with meaningful P/B only.
TEVA' s P/B Range Over the Past 10 Years
Min: 1.36  Med: 2.25 Max: 4.81
Current: 1.87
1.36
4.81
P/S 2.47
TEVA's P/S is ranked higher than
53% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. TEVA: 2.47 )
Ranked among companies with meaningful P/S only.
TEVA' s P/S Range Over the Past 10 Years
Min: 1.58  Med: 2.95 Max: 5.83
Current: 2.47
1.58
5.83
PFCF 42.00
TEVA's PFCF is ranked lower than
70% of the 221 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.52 vs. TEVA: 42.00 )
Ranked among companies with meaningful PFCF only.
TEVA' s PFCF Range Over the Past 10 Years
Min: 8.46  Med: 16.36 Max: 48.73
Current: 42
8.46
48.73
POCF 8.65
TEVA's POCF is ranked higher than
83% of the 292 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.35 vs. TEVA: 8.65 )
Ranked among companies with meaningful POCF only.
TEVA' s POCF Range Over the Past 10 Years
Min: 6.58  Med: 11.73 Max: 23.41
Current: 8.65
6.58
23.41
EV-to-EBIT 24.70
TEVA's EV-to-EBIT is ranked lower than
59% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.71 vs. TEVA: 24.70 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 12  Med: 20.55 Max: 991
Current: 24.7
12
991
EV-to-EBITDA 19.42
TEVA's EV-to-EBITDA is ranked lower than
56% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.97 vs. TEVA: 19.42 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.1  Med: 15.65 Max: 290.6
Current: 19.42
9.1
290.6
PEG 5.98
TEVA's PEG is ranked lower than
80% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.01 vs. TEVA: 5.98 )
Ranked among companies with meaningful PEG only.
TEVA' s PEG Range Over the Past 10 Years
Min: 0.35  Med: 1.68 Max: 119.22
Current: 5.98
0.35
119.22
Shiller P/E 21.40
TEVA's Shiller P/E is ranked higher than
81% of the 151 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 50.39 vs. TEVA: 21.40 )
Ranked among companies with meaningful Shiller P/E only.
TEVA' s Shiller P/E Range Over the Past 10 Years
Min: 18.63  Med: 29.37 Max: 73.59
Current: 21.4
18.63
73.59
Current Ratio 1.32
TEVA's Current Ratio is ranked lower than
78% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. TEVA: 1.32 )
Ranked among companies with meaningful Current Ratio only.
TEVA' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.59 Max: 2.95
Current: 1.32
0.92
2.95
Quick Ratio 1.01
TEVA's Quick Ratio is ranked lower than
75% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. TEVA: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
TEVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.08 Max: 2.19
Current: 1.01
0.63
2.19
Days Inventory 182.49
TEVA's Days Inventory is ranked lower than
78% of the 666 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. TEVA: 182.49 )
Ranked among companies with meaningful Days Inventory only.
TEVA' s Days Inventory Range Over the Past 10 Years
Min: 131.65  Med: 186.40 Max: 208.14
Current: 182.49
131.65
208.14
Days Sales Outstanding 97.21
TEVA's Days Sales Outstanding is ranked lower than
67% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.90 vs. TEVA: 97.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 97.21
95.91
153.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.47
TEVA's Dividend Yield is ranked higher than
73% of the 603 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. TEVA: 2.47 )
Ranked among companies with meaningful Dividend Yield only.
TEVA' s Dividend Yield Range Over the Past 10 Years
Min: 0.49  Med: 1.32 Max: 3.26
Current: 2.47
0.49
3.26
Dividend Payout 0.71
TEVA's Dividend Payout is ranked lower than
79% of the 379 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.34 vs. TEVA: 0.71 )
Ranked among companies with meaningful Dividend Payout only.
TEVA' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.14 Max: 2.83
Current: 0.71
0.04
2.83
Dividend Growth (3y) 15.30
TEVA's Dividend Growth (3y) is ranked higher than
68% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. TEVA: 15.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
TEVA' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -6.7  Med: 27.85 Max: 80.9
Current: 15.3
-6.7
80.9
Forward Dividend Yield 2.50
TEVA's Forward Dividend Yield is ranked higher than
69% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.54 vs. TEVA: 2.50 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 7.07
TEVA's Yield on cost (5-Year) is ranked higher than
93% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. TEVA: 7.07 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TEVA' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.39  Med: 3.75 Max: 9.25
Current: 7.07
1.39
9.25
3-Year Average Share Buyback Ratio 1.20
TEVA's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 422 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. TEVA: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.6  Med: -2.30 Max: 1.2
Current: 1.2
-12.6
1.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.94
TEVA's Price/Projected FCF is ranked higher than
87% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. TEVA: 0.94 )
Ranked among companies with meaningful Price/Projected FCF only.
TEVA' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.58  Med: 1.42 Max: 29.19
Current: 0.94
0.58
29.19
Price/DCF (Earnings Based) 1.39
TEVA's Price/DCF (Earnings Based) is ranked lower than
53% of the 80 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.31 vs. TEVA: 1.39 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.83
TEVA's Price/Median PS Value is ranked higher than
77% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. TEVA: 0.83 )
Ranked among companies with meaningful Price/Median PS Value only.
TEVA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.54  Med: 1.14 Max: 2.01
Current: 0.83
0.54
2.01
Earnings Yield (Greenblatt) (%) 4.04
TEVA's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 844 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. TEVA: 4.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TEVA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 4.90 Max: 8.4
Current: 4.04
0.1
8.4
Forward Rate of Return (Yacktman) (%) 7.98
TEVA's Forward Rate of Return (Yacktman) (%) is ranked higher than
52% of the 325 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. TEVA: 7.98 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TEVA' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 6.8  Med: 18.50 Max: 44.5
Current: 7.98
6.8
44.5

More Statistics

Revenue (TTM) (Mil) $19,480
EPS (TTM) $ 1.93
Beta0.46
Short Percentage of Float2.44%
52-Week Range $48.01 - 72.31
Shares Outstanding (Mil)914.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 22,739 25,429 26,142
EPS ($) 5.38 6.11 6.64
EPS w/o NRI ($) 5.38 6.11 6.64
EPS Growth Rate
(3Y to 5Y Estimate)
7.40%
Dividends Per Share ($) 1.28 1.38 1.65
» More Articles for TEVA

Headlines

Articles On GuruFocus.com
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
Andreas Halvorsen Buys Facebook, Amazon, MasterCard Jun 14 2016 
Growing Generic Drug Market a Good Opportuity for 2 India Firms May 30 2016 
Stocks Near 52-Week Lows May 26 2016 
John Keeley Comments on Teva Pharmaceuticals Apr 26 2016 
Pfizer-Allergen Merger Deal End Hurts Some Funds But Helps Many Apr 08 2016 
Time To Buy Allergan Apr 06 2016 
Health Care Investor Larry Robbins Buys HCA Holdings, Cigna Mar 31 2016 
Fight Market Malaise with These Four Sector Strategies Mar 30 2016 
Bernard Horn Comments on Teva Pharmaceutical Mar 21 2016 

More From Other Websites
[$$] Teva, Allergan Get FTC Approval for Generics Purchase Jul 27 2016
FTC approves Teva's $40.5B deal for Allergan's generics business Jul 27 2016
Teva purchase of Allergan generics business gets OK with conditions Jul 27 2016
Teva Wins U.S. Nod for Actavis After Divestiture of 79 Drugs Jul 27 2016
Teva purchase of Allergan generics business gets OK with conditions Jul 27 2016
Teva purchase of Allergan generics business approved with conditions Jul 27 2016
Teva Receives Clearance from the U.S. Federal Trade Commission for Actavis Generics Acquisition Jul 27 2016
Teva Wins U.S. Approval to Buy Actavis After Selling Generics Jul 27 2016
Short Sellers Get Selective on Major Pharma Jul 27 2016
Alder Biopharma Migraine Drug Holds Up After 6 Months Jul 25 2016
Investor Demand for U.S. Corporate Bond Remains Insatiable Jul 25 2016
Specialty Pharma: Earnings Better Be Good…or Else Jul 25 2016
Investors scrap for Teva Pharmaceutical bonds Jul 22 2016
Teva Announces Pricing of Additional CHF1.0 Billion of Senior Notes in Connection with Pending... Jul 21 2016
Teva Gets Funding to Close Allergan Deal With Franc Bond Sale Jul 21 2016
Teva Announces Pricing of Additional €4.0 Billion of Senior Notes in Connection with Pending... Jul 20 2016
Five high-grade issuers announce deals Jul 20 2016
Teva (TEVA) Stock Down After Pricing in Debt Offering Jul 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)